Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.
Tumor vaccines can induce robust immune responses targeting tumor antigens in the clinic, but antitumor effects have been disappointing. One reason for this is ineffective tumor infiltration of the cytotoxic T lymphocytes (CTLs) produced. Oncolytic viruses are capable of selectively replicating within tumor tissue and can induce a strong immune response. We therefore sought to determine whether these therapies could be rationally combined such that modulation of the tumor microenvironment by the viral therapy could help direct beneficial CTLs induced by the vaccine. As such, we examined the effects of expressing chemokines from oncolytic vaccinia virus, including CCL5 (RANTES), whose receptors are expressed on CTLs induced by different vaccines, including type-1-polarized dendritic cells (DC1). vvCCL5, an oncolytic vaccinia virus expressing CCL5, induced chemotaxis of lymphocyte populations in vitro and in vivo, and displayed improved safety in vivo. Interestingly, enhanced therapeutic benefits with vvCCL5 in vivo correlated with increased persistence of the viral agent exclusively within the tumor. When tumor-bearing mice were both vaccinated with DC1 and treated with vvCCL5 a further significant enhancement in tumor response was achieved which correlated with increased levels of tumor infiltrating lymphocytes. This approach therefore represents a novel means of combining biological therapies for cancer treatment.
Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Jun
J
Li
Mark
M
O'Malley
Julie
J
Urban
Padma
P
Sampath
Z Sheng
ZS
Guo
Pawel
P
Kalinski
Steve H
SH
Thorne
David L
DL
Bartlett
D000818:Animals; D045744:Cell Line, Tumor; D018946:Chemokine CCL5 / Q000235:genetics / Q000378:metabolism*; D003713:Dendritic Cells / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D051379:Mice; D008817:Mice, Mutant Strains; D008819:Mice, Nude; D009369:Neoplasms / Q000628:therapy*; D050504:Oncolytic Viruses / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D014616:Vaccinia virus / Q000235:genetics / Q000378:metabolism / Q000502:physiology*
D018946:Chemokine CCL5
Cancer Res. 2001 Dec 15;61(24):8751-7
11751395
J Natl Cancer Inst. 1991 Mar 20;83(6):433-7
1999850
J Immunol. 2009 Apr 1;182(7):3945-6
19299688
PLoS Pathog. 2008 Jan;4(1):e5
18208323
Lancet Oncol. 2009 Sep;10(9):840-1
19717085
Lancet Oncol. 2009 Sep;10(9):877-84
19656725
Nat Med. 2008 Oct;14(10):1123-7
18836461
Biol Blood Marrow Transplant. 2005 Mar;11(3):181-7
15744236
Blood. 2003 Apr 1;101(7):2797-803
12517816
Blood. 2003 Jan 15;101(2):640-8
12393519
Mol Ther. 2006 Sep;14(3):361-70
16905462
J Immunother. 2007 Oct;30(7):762-72
17893568
PLoS Med. 2007 Dec;4(12):e353
18162040
Expert Rev Anticancer Ther. 2008 Apr;8(4):561-72
18402523
J Leukoc Biol. 2008 Jul;84(1):319-25
18426971
J Immunol. 2010 Jan 15;184(2):591-7
20018619
Clin Cancer Res. 2008 Feb 1;14(3):912-23
18245555
J Immunol. 2009 Feb 1;182(3):1746-55
19155524
Semin Oncol. 2007 Dec;34(6):524-31
18083376
Cancer Immunol Immunother. 2009 Aug;58(8):1329-36
19156413
J Immunother. 2009 Feb-Mar;32(2):145-56
19238013
Cancer Immunol Immunother. 2008 Jul;57(7):977-86
18060404
J Immunol. 1994 Aug 15;153(4):1687-96
7519209
Lancet Oncol. 2008 Jun;9(6):533-42
18495536
Int J Biochem Cell Biol. 2004 Jan;36(1):35-8
14592532
Curr Opin Mol Ther. 2008 Aug;10(4):371-9
18683102
Cancer Immunol Immunother. 2007 Nov;56(11):1795-805
17447064
Curr Gene Ther. 2004 Mar;4(1):41-51
15032613
Cancer Res. 2005 Nov 1;65(21):9991-8
16267024
Cancer Res. 2001 Jan 15;61(2):517-25
11212244
J Clin Invest. 2007 Nov;117(11):3350-8
17965776
Nat Rev Cancer. 2009 Jan;9(1):64-71
19104515
Nat Med. 2005 Oct;11(10):1073-81
16170322
J Exp Med. 2006 Oct 30;203(11):2451-60
17015634
Cancer Res. 2004 Sep 1;64(17):5934-7
15342370
Science. 2006 Mar 24;311(5768):1780-4
16556847
Gene Ther. 2005 Mar;12(5):437-45
15647767
Transplantation. 2005 Jul 15;80(1):134-9
16003245
Mol Ther. 2010 Sep;18(9):1698-705
20606649